Document is current
Any future updates will be listed below
-
Authors
Zhang, Wubing
Brown, Erin L. https://orcid.org/0000-0002-0004-3487
Usmani, Abul https://orcid.org/0000-0001-5485-7323
Earland, Noah
Kang, Minji https://orcid.org/0000-0003-0009-4249
Olelewe, Chibuzor
Viswanathan, Anushka https://orcid.org/0009-0004-8140-8936
Chauhan, Pradeep S.
Steen, Chloé B.
Jeon, Hyun Soo https://orcid.org/0000-0001-8388-2480
Avagyan, Susanna
Alahi, Irfan
Semenkovich, Nicholas P. https://orcid.org/0000-0001-5266-6734
Schwab, Janella C. https://orcid.org/0000-0003-3784-9174
Sachs, Chloe M.
Qaium, Faridi
Harris, Peter K.
Cai, Qingyuan https://orcid.org/0009-0000-9391-2305
Gentles, Andrew J. https://orcid.org/0000-0002-0941-9858
Knight, James
Graham, Rondell P. https://orcid.org/0000-0002-8686-4867
Bacchiocchi, Antonietta
Lucas, Peter C. https://orcid.org/0000-0003-4880-7172
Fields, Ryan C.
Sznol, Mario https://orcid.org/0000-0003-4137-9662
Halaban, Ruth https://orcid.org/0000-0001-8451-1964
Chen, David Y. https://orcid.org/0000-0002-3681-6576
Chaudhuri, Aadel A. https://orcid.org/0000-0003-3115-3061
Newman, Aaron M. https://orcid.org/0000-0002-1857-8172
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 25 March 2026
First Online: 6 May 2026
Competing interests
: M.S. has consulted for Idera Pharmaceuticals, Regeneron Pharmaceuticals, Apexigen, Alligator Bioscience, Verastem Oncology, Agenus, Rubius Therapeutics, Bristol-Myers Squibb, Genentech-Roche, Boston Pharmaceuticals, Servier Laboratories, Adaptimmune Therapeutics, Immunocore, Dragonfly Therapeutics, Pierre-Fabre Pharmaceuticals, Molecular Partners, Boehringer Ingelheim, Innate Pharma, Nektar Therapeutics, Pieris Pharmaceuticals, Numab Therapeutics, Abbvie, Zelluna Immunotherapy, Seattle Genetics, Genocea Biosciences, GI Innovation, Chugai-Roche, BioNTech, Eli Lilly, Modulate Therapeutics, Array Biopharma, AstraZeneca and Genmab. M.S. has stock options in EvolveImmune, NextCure, Repertoire Immune Medicines, Adaptive Biotechnologies, Actym Therapeutics and Amphivena, and has stock ownership in GlaxoSmithKline and Johnson & Johnson. A.A.C. has patent filings and advisory experience related to liquid biopsy and cancer biomarkers. A.A.C. has stock options in Geneoscopy, and ownership interests in LiquidCell Dx and Droplet Biosciences. A.M.N. has patent filings related to digital cytometry, liquid biopsy and cancer biomarkers, and has served as a consultant to, and has ownership interests in, CiberMed and LiquidCell Dx. The other authors declare no competing interests.
